Monoclonal and Polyclonal Antibodies Research

SEP 8, 2026 · JOURNAL ARTICLE

Fungal Lectins: Emerging Glyco-Immune Checkpoint Modulators for Cancer Diagnosis, Prognosis, and Therapy

Glycobiology

A narrative review synthesizing mechanistic and in vitro evidence on fungal lectins as putative immunomodulators and diagnostic probes, with acknowledged absence of clinical validation and translational data.

SEP 7, 2026 · JOURNAL ARTICLE

Complement tumor-crosstalk: the role of C5a receptors in urothelial carcinomas

Frontiers in Immunology

This is a narrative review summarizing existing knowledge about complement C5a receptors in cancer, with limited new primary data on urothelial carcinoma; it raises mechanistic questions rather than reporting a rigorous empirical result.

SEP 6, 2026 · JOURNAL ARTICLE

Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases

Stem Cell Research & Therapy

A narrative review synthesizing advances in CAR-T engineering strategies for multiple disease contexts, offering conceptual direction rather than new empirical evidence or clinical outcomes.

SEP 5, 2026 · JOURNAL ARTICLE

Antibody-Drug Conjugates in the Treatment of Esophageal Cancer

Current Treatment Options in Oncology

Expert opinion and treatment recommendation on ADC use in esophageal cancer, not derived from primary trial data presented in this source.

SEP 4, 2026 · JOURNAL ARTICLE

Generation and characterization of a CEACAM5 x CDH17 x CD3 tri-specific T-Cell engager for colorectal cancer therapy

Antibody Therapeutics

First-in-class tri-specific T-cell engager showing promising preclinical efficacy in xenograft models, but lacks human clinical data and relies on surrogate endpoints and animal studies.

SEP 4, 2026 · JOURNAL ARTICLE

A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers

Cancer Research Communications

First-in-human Phase 1 dose escalation with primary focus on safety and tolerability; anti-tumor activity is secondary and minimal (2.5% ORR), consistent with early-phase exploratory work.

SEP 4, 2026 · JOURNAL ARTICLE

Unlocking the potential of bacteriophage-based therapeutic gene delivery in hepatocellular carcinoma

Journal of the Egyptian National Cancer Institute

This is a narrative review synthesizing preclinical and mechanistic concepts about bacteriophage-mediated gene delivery in HCC, raising questions about therapeutic potential rather than reporting empirical trial results or definitive evidence.

SEP 4, 2026 · JOURNAL ARTICLE

Supramolecular immunomodulatory hydrogelator potentiates CAR-T therapy with long-lasting endogenous immunity toward solid tumor eradication

Science Advances

Preclinical mechanistic study in murine tumor models demonstrating a novel hydrogel delivery platform; no human data, clinical outcomes, or comparative efficacy data reported.